{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:30:53Z","timestamp":1785796253443,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003091","name":"Shandong Province","doi-asserted-by":"publisher","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}],"id":[{"id":"10.13039\/501100003091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bmcl.2019.03.005","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T12:45:21Z","timestamp":1551789921000},"page":"1060-1064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Discovery of novel pyrazole derivatives as potential anticancer agents in MCL"],"prefix":"10.1016","volume":"29","author":[{"given":"Fansheng","family":"Ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bmcl.2019.03.005_b0005","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bmcl.2019.03.005_b0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2017.06.067","article-title":"Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity","volume":"138","author":"Liu","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.03.005_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bmcl.2019.03.005_b0020","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects","volume":"181","author":"Hershkovitz-Rokah","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bmcl.2019.03.005_b0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.bmcl.2019.03.005_b0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.bmcl.2019.03.005_b0035","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma","volume":"136","author":"Bernard","year":"2015","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.bmcl.2019.03.005_b0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.03.005_b0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"14","key":"10.1016\/j.bmcl.2019.03.005_b0050","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bmcl.2019.03.005_b0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0952-7915(00)00221-1","article-title":"Tec kinases: modulators of lymphocyte signaling and development","volume":"13","author":"Lewis","year":"2001","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.03.005_b0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B-cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bmcl.2019.03.005_b0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.bmcl.2019.03.005_b0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2019.03.005_b0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ardp.201700369","article-title":"Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: preclinical and clinical developments of small molecule inhibitors","volume":"351","author":"Zhang","year":"2018","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmcl.2019.03.005_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bmcl.2019.03.005_b0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.bmcl.2019.03.005_b0090","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bmc.2018.03.017","article-title":"Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors","volume":"26","author":"Zheng","year":"2018","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.005_b0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.bmcl.2019.03.005_b0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bmcl.2019.03.005_b0105","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting BTK with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2019.03.005_b0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2019.03.005_b0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2019.03.005_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0988-z","article-title":"HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis","volume":"18","author":"Park","year":"2016","journal-title":"Arthrit Res Ther"},{"key":"10.1016\/j.bmcl.2019.03.005_b0125","unstructured":"Springer JR, Devadas B, Garland DJ. et al. Preparation of pyrazole compounds as BTK (Bruton's tyrosine kinase) inhibitors. CN 105008344 2015 CN 105008344; 2015."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19301313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19301313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:28:41Z","timestamp":1760772521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19301313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0960894X19301313"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.03.005","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel pyrazole derivatives as potential anticancer agents in MCL","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}